Alexandria Real Estate Equities, Inc. Celebrates 20 Years of Prix Galien USA and More than Two Decades of Investing in and Catalyzing Life Science Innovation in New York City

Alexandria Real Estate Equities (ARE) is marking Prix Galien USA’s 20th anniversary and its longstanding partnership with the Galien Foundation.

Rhea-AI Summary

Alexandria Real Estate Equities (ARE) is marking Prix Galien USA’s 20th anniversary and its longstanding partnership with the Galien Foundation.

Alexandria will lead a Galien Forum USA panel in New York City on the MAP-D depression research initiative, for which it provided the first funding. MAP-D completed its design phase in June 2026 and began advancing toward a longitudinal clinical study. The three-year pilot will use artificial intelligence to examine relationships between biological markers and patient outcomes. The anniversary also highlights Alexandria’s history of life science venture investing in New York City, dating to 2002.

Key Figures

Prix Galien USA anniversary: 20 years MAP-D pilot duration: Three years MAP-D design-phase milestone: June 2026

Prix Galien USA anniversary

20 years

Anniversary celebrated in New York City

MAP-D pilot duration

Three years

Pilot using AI models to study biological markers and patient outcomes

MAP-D design-phase milestone

June 2026

Critical design phase completed

Key Terms

longitudinal clinical study, neuroimaging, precision medicine

3 terms

longitudinal clinical study medical

"began advancing toward a first-of-its-kind longitudinal clinical study"

A longitudinal clinical study tracks the same group of patients over months or years to observe how a treatment or disease progresses, rather than taking a one-time snapshot. For investors, these studies reveal long-term safety, effectiveness and durability of a therapy—information that helps assess regulatory risk, future sales potential and whether early positive results will hold up over time, much like watching a sapling grow into a full tree.

neuroimaging medical

"integrating biological, clinical, neuroimaging, digital and patient-reported data"

Neuroimaging is the set of medical techniques that create pictures or maps of the brain’s structure and activity, like using a camera or GPS to see what parts of the brain look like and how they behave. For investors, neuroimaging matters because it provides objective evidence used in clinical trials, product development and regulatory decisions, helping judge whether a therapy or device is likely to work, reduce risk, and reach the market.

precision medicine medical

"aims to establish a scalable precision medicine framework for depression"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif., Oct. 29, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today celebrates the 20th anniversary of the Prix Galien USA in New York City and its longstanding strategic partnership with the Galien Foundation, a premier global organization dedicated to recognizing and advancing scientific innovation that improves human health. For more than two decades, Alexandria has been a driving force in the creation and growth of New York City's commercial life science ecosystem, bringing together mission-critical infrastructure, strategic venture capital and world-class talent to catalyze and grow innovative life science companies.

At today's Galien Forum USA, Alexandria will lead a panel discussion on the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative, titled "Cracking the Code of Depression: The MAP-D Initiative." The panel will feature leading experts in neuroscience research, patient care, policy and drug development including Amit Etkin, MD, PhD, founder and chief executive officer of Alto Neuroscience; Steve Hoffmann, senior vice president and chief preclinical officer of the Foundation for the National Institutes of Health (FNIH); Husseini Manji, MD, professor at Oxford University, chair of the UK Government Mental Health Goals Program and former global head of neuroscience at Johnson & Johnson; and Mark Mintun, MD, group vice president of neuroscience research and development at Eli Lilly and Company. The panel will be co-moderated by Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments and Lynne Zydowsky, PhD, chief of science of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments.

As the FNIH's founding strategic partner on the MAP-D initiative, Alexandria provided the first funding and helped secure the cross-sector support required to launch the pioneering public-private partnership. In June 2026, the MAP-D initiative completed its critical design phase and began advancing toward a first-of-its-kind longitudinal clinical study integrating biological, clinical, neuroimaging, digital and patient-reported data to generate one of the most comprehensive depression research datasets ever assembled. The three-year pilot will leverage advanced artificial intelligence models to identify relationships between biological markers and patient outcomes. Ultimately, the MAP-D initiative aims to establish a scalable precision medicine framework for depression to accelerate scientific discovery and extend its impact beyond depression to other serious mental illnesses, with the potential to serve as a defining blueprint for precision mental health over the next decade.

"For 20 years, the Prix Galien USA has recognized outstanding scientific achievements that have changed the course of human health, and Alexandria is deeply proud of our founding partnership with the Galien Foundation and our shared commitment to advancing life-changing innovation," said Mr. Marcus. "Driven by our noble mission to advance human health, Alexandria Venture Investments (AVI) is the second most active institutional life science investor in NYC, providing strategic capital and expertise to companies pursuing novel approaches across oncology, neuroscience, gene therapy and AI-enabled drug discovery. Our first investment, Intra-Cellular Therapies, Inc. (ITCI), became one of the city's most compelling biotechnology success stories, culminating in its $14.6 billion acquisition by Johnson & Johnson in 2025."

Alexandria's venture investment leadership in NYC dates back to 2002, when AVI participated in ITCI's Series A financing, beginning a longstanding strategic and financial relationship with Sharon Mates, PhD, founder, former chairman and chief executive officer of ITCI. ITCI advanced category-defining neuroscience research from discovery through clinical development, went public and grew into a leading biopharmaceutical company with the commercialization of CAPLYTA®, a treatment for schizophrenia and bipolar depression. Dr. Mates led the company from founding through its historic exit, demonstrating a remarkable commitment to ITCI and the NYC life science ecosystem. Mr. Marcus served on ITCI's board of directors from 2006 through its acquisition.

In October 2025, AVI participated in the oversubscribed $101 million Series A financing of NYC-based Nilo Therapeutics (Nilo), alongside leading life science investors and the Gates Foundation. Nilo represents a new generation of innovative companies emerging from NYC's world-class life science ecosystem. The company is developing a novel class of medicines designed to harness the body's neural circuits to regulate immune function and inflammation, with the potential to address a broad range of immune-mediated diseases.

Eikon Therapeutics (Eikon), an AVI portfolio company with its East Coast operations at the Alexandria Center® for Life Science – NYC, is advancing a pipeline of oncology medicines under the leadership of renowned pharmaceutical executive Roger Perlmutter, MD, PhD. In February 2026, Eikon completed an upsized $381 million initial public offering, marking a significant milestone and demonstrating the continued growth of an AVI-backed company within Alexandria's NYC ecosystem.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. Founded in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com.

Forward-Looking Statements 
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the development and potential therapeutic applications of medicines being pursued by Alexandria Venture Investments' portfolio companies; the anticipated timing, launch, scope, duration and conduct of the MAP-D initiative and its pilot phase; the use of artificial intelligence and other data-analysis methods in the initiative; the initiative's ability to identify relationships between biological markers and patient outcomes, inform more personalized treatment approaches, accelerate scientific discovery and improve patient outcomes; and Alexandria's role in and support of the initiative, its collaboration with the FNIH and the anticipated impact and benefits of such support and collaboration. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the availability and timing of funding; the receipt of required approvals; participant recruitment and retention; the performance of collaborators; scientific, technical and operational challenges; and changes in the initiative's design, scope, timing or cost, as well as the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update or revise any forward-looking statement, except as required by law. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

CONTACT: Sara Cohen, Assistant Vice President – Capital Markets & Corporate Operations, (646) 799-2617, scohen@are.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-celebrates-20-years-of-prix-galien-usa-and-more-than-two-decades-of-investing-in-and-catalyzing-life-science-innovation-in-new-york-city-302922762.html

SOURCE Alexandria Real Estate Equities, Inc.